Chapter 56: Vaginitis – Antifungal & Antibacterial Treatments

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we're tackling a pretty dense chapter on pharmacotherapeutics, the kind usually aimed at advanced practice students.

Our goal here is to really cut through all that clinical detail about treating vaginitis.

We want to pull out the key drug facts, make them conversational,

easy to grasp, like quick nuggets you can actually remember.

Exactly.

And for this deep dive, we're keeping it really laser focused actually on just the infectious causes.

So we're going to untangle the drug choices for what we call the big three, bacterial vaginosis or BV vulvavaginal candidiasis, VVC, that's yeast infections, and trichomonas vaginalis, which is a protozoan.

They each need different treatments, so getting those pharmacological decision points right is, well, it's critical.

Okay, great.

So before we even talk drugs or infections, let's lay the groundwork, the foundation.

What does a normal, healthy vaginal environment actually look like?

What protects it?

Right, it really boils down to chemistry and the local ecology there.

The number one defense is maintaining a very acidic pH.

We're just passive.

It's actively maintained by specific strains of lactobacillus bacteria, the ones that produce hydrogen peroxide.

So lactobacillus are the good guys here, the defenders,

and hydrogen peroxide is sort of their weapon.

That's a perfect way to put it.

Think of them as tiny biological shield generators.

Now, when things disrupt that, balance things like antibiotics, maybe hormonal shifts, certain hygiene products, even just frequent sexual activity that can disrupt the flora, the pH starts to creep up, those shields effectively drop, and boom, you've created an opening for opportunistic infections like BV or yeast.

That whole disruption process, that's really the core pathophysiology of vaginitis.

Got it.

So understanding that pH defense is absolutely fundamental.

Okay, knowing that, let's quickly map out our targets.

What are the clinical signs for these big three?

Because treatment's no good if the diagnosis is wrong.

Good point.

Let's start with bacterial vaginosis, BV.

The classic textbook presentation is a homogenous sort of thin grayish -white discharge that has a distinct malador, often described as fishy.

But, and this is a big but, here's the clinical trap.

Up to 84 % of women with BV might have absolutely no symptoms.

84%.

Wow.

So how do you diagnose it then, especially in an office setting?

That's where the AMSOIL criteria come in.

It's a set of four signs clinicians look for during a rapid office assessment.

You need three out of the four.

So number one, that homogenous discharge we mentioned.

Two, a vaginal pH over 4 .5.

Remember, normal is below 4 .5.

Right.

Higher pH means less acidic.

Defense is down.

Exactly.

Three, a positive whiff test.

That's when you add a drop of potassium hydroxide, KOH, to the discharge sample and you get that characteristic fishy smell.

And four, the presence of clue cells.

When you look at the sample under the microscope, those are vaginal epithelial cells studded with bacteria.

Okay, so AMSOIL criteria for BV.

Now, how does that compare to VVC, the yeast infection?

That usually feels different, doesn't it?

Oh, absolutely.

VVC is often, you know, intensely symptomatic.

The hallmark is usually severe itching pruritus, along with redness, erythema.

And then there's that characteristic thick white, often described as curd -like or cottage cheese -like discharge.

It tends to stick to the vaginal walls.

And crucially, unlike BV, the vaginal pH in VVC is typically normal.

It stays below 4 .5.

Okay, pH normal for VVC.

And diagnosis.

Usually confirmed by seeing pseudohyphae or budding yeast on that KOH wet mount prep under the microscope.

Got it.

And the third one, trichomoniasis.

What makes that protozoan infection stand out or maybe harder to spot?

Well, trichomonas vaginalis often presents with a really profuse, sometimes frothy green yellowish discharge that can also be malodorous.

But like BV, it can be sneaky.

Up to 86 % of infections might be asymptomatic.

That's quite high.

Yeah, another tricky one.

And the challenge with diagnosis using just a standard wet mount is that you need to see the live motile trichomonads.

They can be hard to spot or might not be viable by the time you look.

So the current recommendation, pretty strongly from the CDC actually, is to use molecular testing.

Specifically, nucleic acid amplification tests or NATs.

They're just much, much more sensitive.

NATs for trich, makes sense.

Yeah.

Okay, so we've got our diagnosis nailed down.

Let's talk treatment goals.

What are we trying to achieve here beyond just, you know, killing the bug?

Well, the first and most immediate goal is obviously rapid symptom relief, the itching, the discharge, the odor.

These can cause significant physical discomfort and, frankly, emotional distress too.

But right alongside that, we need to raise a really serious warning flag about self -treatment, particularly for suspected yeast infections.

Oh, why that?

Because studies have shown that self -diagnosis of EVC is surprisingly inaccurate.

One study mentioned in the source found it was only correct about 34 % of the time.

Wait, hold on.

Only a third of women buying OTC yeast treatments actually have a yeast infection.

Yeah.

What about the other two thirds then?

Exactly.

They're delaying getting the right diagnosis and the right treatment for what they actually have.

That could be DV, it could be trich, or sometimes even more concerningly, it could be something like pelvic inflammatory disease, PID.

They're using a medication that won't work and the underlying condition is just continuing untreated.

It's a huge patient safety issue.

That's a critical point.

Okay, are there other specific goals, say for BV?

Yes, for BV specifically, treatment also aims to reduce the risk of certain complications.

Things like post -operative infections after gynecological procedures like an abortion or a hysterectomy.

There's also some thought it might reduce the risk of acquiring other STIs.

But wasn't there a caveat about treating everyone with BV?

Yes, very important distinction.

Routine screening and treatment for women who have BV but are asymptomatic is generally not recommended.

The evidence just doesn't consistently show that treating it in the absence of symptoms prevents those longer -term complications.

So we treat symptomatic women for relief and risk reduction, but we don't typically screen and treat asymptomatic cases across the board.

Okay, that clarifies things.

Let's dive into the drugs now, starting with VVC, yeast infections.

The first -line treatments are usually the Azoles, right?

How do you choose between,

say, a topical cream and an oral pill?

Right, for uncomplicated VVC, you've got both topical and oral Azole options and they're both highly effective.

We're talking 80 to 90 percent cure rates, generally.

The topical Azoles include drugs like Clotrimazole, Myconazole, Botoconazole, Teconazole.

Some of these are available over the counter, some prescription.

They come as creams or vaginal suppositories, and the treatment duration can vary.

You might see one -day, three -day, seven -day, even 14 -day regimens.

They're generally considered better than the older drug Nistatin for these simple infections.

And then there's the oral option, which is super popular.

Yes, oral

usually given as a single, one -time 150 -milligram dose.

It's just as effective as the topical treatments and, well, the convenience factor and patient acceptance are obviously very high.

Now, before we move on from topicals, there's a really crucial counseling point.

It's more than just a side effect note.

It's a potential safety issue, isn't it?

Absolutely paramount.

Many of these topical Azole creams and suppositories use an oil -based vehicle.

And here's the critical interaction.

Oil -based topical products can weaken latex.

This includes latex condoms and diaphragms.

So the barrier method could fail.

Precisely.

Clinicians must tell patients to check the product label.

If they rely on latex barrier contraception, they need to understand its effectiveness could be compromised during treatment and for a few days after using the topical agent.

That conversation has to happen.

Definitely.

Okay, shifting gears slightly.

What if the VVC keeps coming back?

What's defined as recurrent VVC and how does treatment escalate?

Yeah, recurrent VVC or RVVC is defined as having four or more documented episodes within a one -year period.

Treatment becomes more intensive, kind of a tiered approach.

If the standard single dose or short topical course isn't enough, step one might be a longer duration therapy.

So maybe seven to 14 days of a topical Azole or switching to multiple doses of oral Flucom Azole, typically doses given 72 hours apart.

Okay, longer initial treatment.

And if that still doesn't work.

If RVVC persists despite that, then you move to a more aggressive strategy.

It usually involves an initial induction phase of treatment for 10 to 14 days using either topical or oral Azoles, followed by a long -term maintenance phase.

This often means taking oral Flucom Azole 150 milligrams just once a week, but potentially for six months.

It's quite a commitment.

Wow, six months.

Okay.

And what happens if lab tests show it's not the usual Candida albicans, but maybe a resistance species like Candida glabrata?

Those don't respond well to avols, do they?

No, they often don't.

C.

glabrata and another one, C.

crusae, frequently show inherent resistance, especially to Fluconazole.

This makes treatment much trickier.

The options become pretty limited and you might need to consult a specialist.

The main alternatives mentioned in the source material are things like

boric acid capsules.

That's 600 milligrams daily for 14 days.

Boric acid.

Yeah.

Or nastatin suppositories, the hundred thousand unit ones, also for 14 days.

But the catch is these often have to be specially compounded by a pharmacy, which can make them expensive and harder to access.

Right.

Not straightforward.

Okay.

That covers VDC pretty well.

Let's pivot now to bacterial vaginosis and trichomoniasis.

Here, the main players are often the nitroimidazoles, specifically metronidazole and tinnidazole.

Correct.

Metronidazole is really the workhorse for both conditions.

For BV, the standard first line recommendation is oral metronidazole, 500 milligrams taken twice a day for seven days.

There are alternatives, including topical options like metronidazole gel, 0 .75 % applied vaginally,

or clindamycin cream, 2%.

Ah, clindamycin cream.

Does that come with the same warning about latex products we discussed with the azole?

It absolutely does.

Topical clindamycin cream and also the clindamycin ovules are formulated in an oleaginous, an oil base.

So same warning applies.

Patients need to know these can weaken latex condoms or diaphragms.

The duration of risk is usually about three to five days after finishing treatment, depending on the specific product.

Crucial reminder.

Okay, moving over to trichomoniasis, what's the go -to dosing strategy there?

And what's absolutely essential for successful treatment?

For trich, the preferred regimens, often due to convenience and efficacy, are single dose therapies.

Either a single two gram dose of metromidazole or a single two gram dose of tindazole.

Tindazole might have slightly fewer GI side effects for some people.

An alternative is the same regimen as BV.

Metronidazole 500 milligrams twice daily for seven days.

But the absolutely mandatory part for trichomoniasis, and this is different from BV, is partner treatment.

Partner treatment.

Mandatory.

Yes.

Trich is sexually transmitted, so treating only the patient without treating their sexual partners almost guarantees reinfection.

Both the patient and their partners need to be treated simultaneously.

And critically, they must abstain from intercourse until both or all have completed the full course of therapy and are completely symptom free.

That's a non -negotiable point for trich.

Okay, now let's hammer home what might be the single most important patient education point for both metronidazole and tindazole.

The alcohol reaction.

It's just saying avoid alcohol enough.

How severe is this reaction?

It's definitely not enough to just casually mention it.

This isn't just, you know, mild nausea if you have a drink.

We're talking about a potential disulfiram -like reaction.

Think severe, acute nausea, often leading to violent vomiting, flushing, headache, potentially even a dangerous drop in blood pressure if someone consumes alcohol while taking these drugs.

Wow.

Okay, so not just beer or wine.

No, any form of alcohol.

That includes things people might not think about like some liquid medications, cough syrups, even some mouth washes that contain alcohol.

The rule is strict abstinence during the entire treatment course and this is key for at least three full days, 72 hours after the last dose.

The drug needs time to clear the system.

It's a truly miserable debilitating reaction they need to avoid.

72 hours after.

Got it.

Okay, super important.

Let's briefly touch on special populations before we wrap up.

How does treatment change during pregnancy?

Right.

In pregnancy, the main goal shifts primarily to relieving the mother's symptoms, as treatment hasn't definitively been proven to prevent adverse pregnancy outcomes like preterm birth across the board.

So for VVC during pregnancy, only topical azoles are recommended, usually for a full seven -day course.

Oral flaconazole is generally avoided.

For symptomatic BV and for trichomoniasis in pregnancy, oral metronidazole is considered the treatment of choice.

Tenadazole is contraindicated due to lack of safety data.

And specifically for trich in pregnancy, the recommended dose is that single two -gram oral dose of metronidazole.

Okay, and what about patients who are immunocompromised, maybe someone living with HIV?

Good question.

Immunocompromised patients often need a sort of more robust or longer treatment courses.

For VVC, they might benefit from those longer seven to 14 -day topical regimens or the three -dose oral flaconazole strategy we mentioned earlier.

For trichomoniasis in HIV -positive individuals, the evidence actually suggests that the seven -day course of metronidazole, 500 milligrams twice daily, is more effective than the single two -gram dose.

So the longer course is often preferred there.

Makes sense.

And just quickly, what about non -infectious causes, things like irritation or atrophy?

Yeah, completely different ballpark for treatment.

If it's atrophic vaginitis, typically seen in postmenopausal women due to low estrogen, the treatment is hormone replacement therapy, often using topical estrogen creams directly.

If it's more of a general inflammatory vaginitis, maybe from an irritant, treatment might involve a short course of a mild topical steroid preparation just to calm down that inflammation.

Right, treating the underlying cause.

Okay, this has been a great breakdown.

Can you maybe synthesize the core drug selection principles one more time?

Absolutely.

Thinking broadly,

VVC generally points you towards the either topical or oral fluconazole, depending on severity and recurrence.

BV and trichomoniasis point you towards the nitromidazoles, metronidazole, or tinnidazole, with clindamycin being a key alternative, especially topical clindamycin for BV.

But the absolute linchpin holding all this together is getting the diagnosis right in the first place.

Accurate diagnosis before starting therapy is essential to avoid treatment failure and delays.

Perfect summary.

Okay, let's crystallize three really crucial takeaways for everyone listening.

First,

you absolutely must ask about alcohol use when prescribing metronidazole or tinnidazole, and you have to really drive home that 72 -hour abstinence rule after treatment stops.

Non -negotiable.

Second, don't forget to educate patients about the risk of latex barrier product impairment condoms, diaphragms, with any oil -based topical.

That means the topical azoles and topical clindamycin.

Yep, both classes.

And third,

recognize that managing recurrent VVC, or infections caused by non -albicans species like C.

glabrata, is often way more complex.

It might require a specialist input or using left common agents like boric acid.

Definitely steps beyond the basics.

All right, that leads us to our final thought for you to ponder.

We heard that statistic only about a third of women self -diagnosing VVC are correct.

So, given this really high rate of self -miss diagnosis, what are the systemic changes or maybe barriers we need to overcome to help more women access accurate, rapid testing like those NATs we talked about before they even reach for an over -the -counter product?

How do we bridge that gap between accessibility and accuracy?

That's a really important question about balancing self -care with good diagnostics.

Something to think about.

Thank you so much for breaking all that down today.

We hope this deep dive leaves you feeling clearer and more confident for your next clinical encounter.

Thanks for joining us.